RINVOQ (upadacitinib) is indicated for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to methotrexate (MTX). RINVOQ may be used as monotherapy or in combination with MTX or other nonbiologic disease-modifying antirheumatic drugs (DMARDs).
One dose, one tablet, once a day
Once-daily oral treatment for your adult patients with moderate to severe active rheumatoid arthritis who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs)
Download the prescribing guide to get started
Dosing recommendations1
- The recommended dose of RINVOQ is one 15-mg tablet once a day, with or without food
The tablet should be swallowed whole, and should not be split, crushed, or chewed
Take RINVOQ at the same time every day
RINVOQ can be taken as monotherapy or in combination with methotrexate.
Please consult the Summary of Product Characteristics for further details regarding monitoring requirements and contraindications prior to initiating RINVOQ.
I want to receive more information via a product specialist.
I have a question for Medical Information.
Reference
- RINVOQ [Summary of Product Characteristics]. AbbVie Deutschland GmbH & Co. KG; May 2021.